title: Localized heuristic inverse quantitative structure activity relationship with bulk descriptors using numerical gradients.
abstract: State-of-the-art quantitative structure-activity relationship (QSAR) models are often based on nonlinear machine learning algorithms, which are difficult to interpret. From a pharmaceutical perspective, QSARs are used to enhance the chemical design process. Ultimately, they should not only provide a prediction but also contribute to a mechanistic understanding and guide modifications to the chemical structure, promoting compounds with desirable biological activity profiles. Global ranking of descriptor importance and inverse QSAR have been used for these purposes. This paper introduces localized heuristic inverse QSAR, which provides an assessment of the relative ability of the descriptors to influence the biological response in an area localized around the predicted compound. The method is based on numerical gradients with parameters optimized using data sets sampled from analytical functions. The heuristic character of the method reduces the computational requirements and makes it applicable not only to fragment based methods but also to QSARs based on bulk descriptors. The application of the method is illustrated on congeneric QSAR data sets, and it is shown that the predicted influential descriptors can be used to guide structural modifications that affect the biological response in the desired direction. The method is implemented into the AZOrange Open Source QSAR package. The current implementation of localized heuristic inverse QSAR is a step toward a generally applicable method for elucidating the structure activity relationship specifically for a congeneric region of chemical space when using QSARs based on bulk properties. Consequently, this method could contribute to accelerating the chemical design process in pharmaceutical projects, as well as provide information that could enhance the mechanistic understanding for individual scaffolds.
authors.affiliation: Computational Toxicology, Global Safety Assessment, AstraZeneca R&D, Pepparedsleden 1, 43153 Mölndal, Sweden. jonna.stalring@astrazeneca.com
authors.forename: Jonna
authors.initials: J
authors.lastname: Stålring
authors.forename: Pedro R
authors.initials: PR
authors.lastname: Almeida
authors.forename: Lars
authors.initials: L
authors.lastname: Carlsson
authors.forename: Ernst
authors.initials: E
authors.lastname: Helgee Ahlberg
authors.forename: Catrin
authors.initials: C
authors.lastname: Hasselgren
authors.forename: Scott
authors.initials: S
authors.lastname: Boyer
mesh_terms: D000465:Algorithms; D055808:Drug Discovery / Q000379:methods*; D005167:Factor VII / Q000037:antagonists & inhibitors; D006801:Humans; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D021281:Quantitative Structure-Activity Relationship; D012044:Regression Analysis; D015203:Reproducibility of Results; D014357:Trypsin / Q000378:metabolism; D014361:Trypsin Inhibitors / Q000737:chemistry / Q000494:pharmacology
chemical_list: D014361:Trypsin Inhibitors; D005167:Factor VII; D017027:Protein Tyrosine Phosphatases; D014357:Trypsin